Table 2 Most Common Treatment-Related Toxicities Experienced During First 16 Weeks
Toxicity | Number of Subjects by Maximum CTC Grade | Total | |||
|---|---|---|---|---|---|
| Â | TACE-BEV (N = 15) | TACE-O (N = 14) | Â | ||
| Â | Grade 1-2 | Grade 3-4 | Grade 1-2 | Grade 3-4 | Â |
Anemia | 3 | 0 | 5 | 1 | 9 |
Anorexia | 5 | 0 | 4 | 0 | 9 |
Bleeding | 8 | 0 | 0 | 1 | 9 |
Constipation | 4 | 0 | 3 | 0 | 7 |
Electrolyte Abnormalities | 5 | 4 | 8 | 1 | 18 |
Elevated Alkaline Phosphatase | 4 | 0 | 3 | 0 | 7 |
Elevated Transaminases | 1 | 14 | 3 | 11 | 29 |
Fatigue | 9 | 0 | 8 | 0 | 17 |
Hyperbilirubinemia | 6 | 2 | 7 | 0 | 15 |
Hypertension | 3 | 3 | 1 | 3 | 10 |
Hypoalbuminemia | 5 | 0 | 7 | 0 | 12 |
Nausea and/or Vomiting | 6 | 0 | 9 | 0 | 15 |
Pain | 9 | 2 | 12 | 1 | 24 |
Proteinuria | 7 | 1 | 1 | 0 | 9 |
Pyrexia | 8 | 0 | 7 | 0 | 15 |
Thrombocytopenia | 4 | 3 | 10 | 0 | 17 |